Amgen announces Artificial Intelligence Partnership with Mila

安进宣布与Mila建立人工智能合作伙伴关系

2021-03-17 01:00:10 BioSpace

本文共1259个字,阅读需4分钟

MONTREAL, March 16, 2021 /CNW/ - Amgen announced today that it has entered into a multi-year partnership with Mila – Quebec Artificial Intelligence Institute. One of the world's leading biotechnology companies, Amgen uses cutting-edge science and technology to discover and develop innovative therapeutics, and AI is currently deployed in several of its R&D and manufacturing activities. This new partnership will permit Amgen to expand its knowledge of AI and deep learning by interacting and engaging with experts in Mila's unique ecosystem, both virtually and on the Mila campus in Montreal. This announcement was made during Effervescence 2021, an international virtual gathering of scientists, entrepreneurs and industry professionals from the life sciences and health technology sectors in the presence of the Quebec Minister of Economy and Innovation, Pierre Fitzgibbon. "We are very happy to have signed this partnership with Mila," said Philip Tagari, Amgen's Vice President of Research, Therapeutic Discovery. "AI is a powerful and innovative tool, and is affecting every step of drug discovery, from better understanding the biological mechanisms of disease and designing molecules to predicting clinical responses and safety profiles. Mila is recognized as being at the global forefront in deep learning and we are excited by the opportunity of combining Mila's world-renowned expertise with Amgen's use of AI in drug development, as well as the possibility of engaging with a uniquely talented group of young AI professionals," he added. "In Mila we see a strong example of Quebec's leadership in AI and in healthcare innovation," stated Brian Heath, Vice President and General Manager of Amgen Canada. "We are eager to explore the synergies between Mila's expertise and Amgen's mission to serve patients as we continue to develop the next generation of innovative medicines." "More and more of Mila's world-class AI experts have research interests at the intersection of AI and life sciences, recognizing the incredible potential of AI-driven solutions for healthcare and pharmaceutical R&D activities," explained Stéphane Létourneau, Executive Vice President at Mila. "Meaningful collaborations, such as this newly established partnership between Amgen and Mila, are essential in order to maximize the full potential of AI for health innovation. We are excited to welcome Amgen within our scientific community and to consolidate our efforts towards advancing and accelerating drug discovery and development." About Amgen Canada As a leader in innovation, Amgen Canada understands the value of science. With main operations located in Mississauga, Ontario's vibrant biomedical cluster, and its research facility in Burnaby, B.C., Amgen Canada has been an important contributor to advancements in science and innovation in Canada since 1991. The company contributes to the development of new therapies and new uses for existing medicines in partnership with many of Canada's leading healthcare, academic, research, government and patient organizations. To learn more about Amgen Canada, visit www.amgen.ca.  About Mila Founded by Professor Yoshua Bengio of the Université de Montréal, Mila is a research institute in artificial intelligence which rallies over 700 researchers specializing in the field of deep learning. Based in Montreal, Mila's mission is to be a global pole for scientific advances that inspires innovation and the development of AI for the benefit of all. Mila is a non-profit organization recognized globally for its significant contributions to the field of deep learning, particularly in the areas of language modelling, machine translation, object recognition and generative models. For more information, visit Mila.quebec. SOURCE Amgen Canada
蒙特利尔2021年3月16日电/CNW/--安进今天宣布,与Mila-Quebec人工智能研究所达成多年合作伙伴关系。作为全球领先的生物技术公司之一,安进利用尖端科技发现和开发创新治疗学,目前在其多个研发和制造活动中都部署了AI。这一新的合作伙伴关系将允许安进通过与Mila独特生态系统中的专家进行互动和接触,无论是在虚拟环境中还是在蒙特利尔的Mila园区,来扩大其对AI和深度学习的了解。这一宣布是在Expervescence 2021期间宣布的,这是一次由生命科学和卫生技术部门的科学家、企业家和行业专业人士参加的国际虚拟集会,魁北克省经济和创新部长Pierre Fitzgibbon出席了会议。 “我们很高兴与Mila签署了这一合作伙伴关系,”安进公司负责研究、治疗发现的副总裁Philip Tagari说。他补充说:“人工智能是一种强大的创新工具,正在影响药物研发的每一个步骤,从更好地理解疾病的生物机制、设计分子到预测临床反应和安全性。Mila被公认为是深度学习领域的全球最前沿,我们很高兴有机会将Mila享誉全球的专业知识与安进在药物开发中使用人工智能相结合,并有可能与一群才华横溢的年轻人工智能专业人员合作。” Amgen加拿大公司副总裁兼总经理Brian Heath说:“在Mila中,我们看到了魁北克在人工智能和医疗创新方面的领导地位。“在我们继续开发下一代创新药物的过程中,我们渴望探索Mila的专业知识与安进为患者服务的使命之间的协同作用。” Mila执行副总裁Stéphane Létourneau解释说:“越来越多的Mila世界级人工智能专家对人工智能和生命科学的交叉领域有研究兴趣,他们认识到人工智能驱动的解决方案在医疗保健和制药研发活动中的不可思议的潜力。”“有意义的合作,如安进与Mila之间新建立的伙伴关系,对于最大限度地发挥人工智能在健康创新方面的全部潜力是至关重要的。我们很高兴在我们的科学界欢迎安进,并巩固我们在推进和加速药物发现和开发方面的努力。” 关于安进加拿大 作为创新的领导者,加拿大安进深知科学的价值。安进加拿大公司的主要业务位于安大略省生机勃勃的生物医学集群密西沙加,其研究设施位于不列颠哥伦比亚省伯纳比,自1991年以来,该公司一直是加拿大科学和创新发展的重要贡献者。该公司与加拿大许多领先的医疗保健、学术、研究、政府和病人组织合作,为现有药物的新疗法和新用途的开发做出贡献。欲了解更多关于加拿大安进公司的信息,请访问www.Amgen.ca。 关于Mila Mila由蒙特利尔大学的约书亚·本吉奥教授创立,是一个人工智能研究机构,聚集了700多名深度学习领域的研究人员。Mila以蒙特利尔为基地,其使命是成为科学进步的全球一极,激发创新和人工智能的发展,造福所有人。Mila是一个全球公认的非营利组织,它对深度学习领域做出了重大贡献,特别是在语言建模、机器翻译、对象识别和生成模型等领域。欲了解更多信息,请访问Mila.Quebec。 资料来源加拿大安进

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文